Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases

June 29, 2022

Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million grant from the Flemish Agency for Innovation and Entrepreneurship (VLAIO). The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates.

Through its unique platform technology, Confo Therapeutics develops GPCR modulators for patients with severe and underserved diseases, with a specific focus on rare diseases. Among other things, the company intends to address an important target for neurological orphan conditions which is currently considered to be an undruggable GPCR.

The research pursued under the aegis of this VLAIO grant will allow Confo Therapeutics to unlock new potential treatments for unmet disease areas and to simultaneously pursue new technology developments. This should ultimately shorten drug discovery timelines and expand their proprietary pipeline for rare disease indications.

Latest stories

Spectacular Breakthrough in Sepsis Research: Vitamin B1 Stops Deadly Lactate Production and Opens the Door to a New Treatment

Ghent, July 29, 2025 – Scientists in Ghent have achieved a major breakthrough in sepsis research. In a study on mice, the researchers demonstrate that vitamin B1 (thiamine pyrophosphate, TPP) restores mitochondrial energy metabolism, drastically reduces lactate production, and increases survival rates in sepsis. The study results were published in Cell Reports.

press.vib.be

Scientists discover brain switch that controls freeze-or-flight survival instincts

Leuven, Belgium, 23 July 2025 – Researchers have identified a key neural switch that controls whether animals instinctively flee from a threat or freeze in place. By comparing two closely related deer-mouse species, they found that this switch is calibrated by evolution to match the animal's habitat. This neural circuit is hypersensitive in mice living in densely vegetated environments, causing instant escape, but less responsive in their open-field cousins, who are more likely to freeze. In doing so, the research team uncovered an important way in which evolution fine-tunes the brain for survival.

press.vib.be

Groundbreaking Study Offers a Novel Approach to Enhance Neuromuscular Function in Patients with Duchenne Muscular Dystrophy

Findings published in The American Journal of Pathology identify GLUD1 enzyme as a potential therapeutic target for muscle restoration through metabolic reprogramming, addressing clinically unmet need for treatment beyond symptom relief

press.vib.be

Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases

Share

Latest stories

About VIB

Contact